The pilot trial is to begin in mainland China with the first patient expected to be enrolled in 1H. Potential to expand into Hong Kong, Macao, and Taiwan, with Senti retaining all commercialisation rights outside of those regions and mainland China. Up to $156 million in development milestones and potential tiered royalties post-commercialisation.
Market Data 
Markets 
